Clinical Trials · NCT02212067
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 87
- Start date
- Aug 2014
- Locations
- 1 site, Germany
- Primary endpoint
- Area under the serum insulin concentration time curve from 0 to 10 minutes after a 25 g glucose bolus i.v. infusion (IVGTT,intravenous glucose tolerance test) over 2 minutes